

Product datasheet for **KN502988**

Cdc73 Mouse Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	Cdc73
Locus ID:	214498



[View online »](#)

Components:
KN502988G1, Cdc73 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)

KN502988G2, Cdc73 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)

KN502988D, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCCGAG AAGTTGGGG GAGGGGTCCG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGGTAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCG CTTTTCCCG AGGGTGGGG AGAACCCTAT
ATAAGTCAG TAGTCGCCG GAACGTTCT TTTCCGAACG GGTTCGCCG CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCT GGCCTCTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTTCCACCTG
GCTGCAGTAC GTGATTCTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGG AGAGTTCGAG GCCTTGCGCT
TAAGGAGCCC CTTCGCCTG TGCTTGAGT GAGGCCTGCC CTGGGCGCTG GGGCCCGCG GTGCGAATCT
GGTGGCACCT TCGCGCCTG CTCGCTGCT TCGATAAGT TCTAGCCATT TAAAATTTT GATGACCTGC
TGCAGCGCT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTGCGTT
TTTGGGGCCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCAGGCGG GGCCTGCGAG
CGCGGCCACC GAGAATCGGA CGGGGGTAGT CCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCGCCCT GGGCGGCAAG GCTGGCCCG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGTTCCCG GCCCTGTGC AGGGAGCTCA AAATGGAGGA CGCGGCGCTC GGGAGAGCGG GCGGGTGAAGT
CACCCACACA AAGGAAAAGG GCCTTCCCGT CCTCAGCCG CGCTTCATGT GACTCCACGG AGTACCGGGC
GCCGTCAGG CACCTCGATT AGTTCTCGAG CTTTTGGAGT ACGTCGTCTT TAGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTTCCCA CACTGAGTGG GTGGAGACTG AAGTTAGGCC AGCTTGGCAG TTGATGTAAT
TCTCCTTGGG ATTTGCCCTT TTTGAGTTT GATCTTGGTT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCCGAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA
CGTGATGGG TACGGCTTCT ACCACTTCG CACCTACCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACACCCG ATCGAGAAGT ACGAGGACGG CGGCGTGCTG CACGTGAGCT
TCAGTACCG CTACGAGGC GCGCGCTGA TCGGCGACTT CAAGGTGATG GGCACCGGCT TCCCGGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGCGGAT
AACGATCTGG ATGGCAGCTT CACCCGACC TTCAGCCTGC GCGACGGCGG CTACTACAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCA TGTTCCCTT
CCGCCCGTG GAGGAGGATC ACAGCAACAC CGAGTGGGG ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTAACCTCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCCTGGA CCTATGACCG AGTACAAGC CACGGTGC GCCTGCCACC GCGACGACGT
CCCCAGGGCC GTACGCACC TCGCCGCCG GTTCGCCGAC TACCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAATCT TCCTCACGG CGTCGGGCTC GACATCGGCA
AGGTGTGGT CGCGGACGAC GCGCCCGCG TGGCGGTCTG GACCACGCC GAGAGCGTCG AAGCGGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGGGC TGGCCCGCA GCAACAGATG
GAAGGCCTCC TGGCGCCGA CCGGCCAAG GAGCCCGCT GTTTCCTGG CACCCTCGG GTCTCGCCG
ACCACCAGG CAAGGTCTG GGCAGCGCG TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTTCT CTGGAGACT CCGCGCCCG CAACCTCCC TTCTACGAG GGCTCGGCT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTGA TGACCCGCA GCCCGGTGCC TGAAACTTGT
TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAG CATTTTTTTC
ACTGCATTCT AGTTGTGGT TGTCCAACT CATCAATGTA TCTTAATAAC TTCGTATAAT GTATGCTATA CGAAGTTAT
    
```



Disclaimer:	These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
RefSeq:	NM_145991
UniProt ID:	Q8JZM7
Synonyms:	8430414L16Rik; C81219; C130030P16Rik; Hrpt2
Summary:	<p>Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors (By similarity). [UniProtKB/Swiss-Prot Function]</p>

Product images:

